Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research
  Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login  
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 242       

   Table of Contents      
COMMENTARY
Year : 2017  |  Volume : 146  |  Issue : 1  |  Page : 8-10

Minimalistic immunohistochemical approach to non-small cell carcinoma of the lung in small biopsies in the context of the 2015 WHO Classification of Lung Cancer


Department of Pathology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry 605 006, India

Date of Web Publication22-Nov-2017

Correspondence Address:
Neelaiah Siddaraju
Department of Pathology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry 605 006
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijmr.IJMR_1069_17

Rights and Permissions

How to cite this article:
Siddaraju N. Minimalistic immunohistochemical approach to non-small cell carcinoma of the lung in small biopsies in the context of the 2015 WHO Classification of Lung Cancer. Indian J Med Res 2017;146:8-10

How to cite this URL:
Siddaraju N. Minimalistic immunohistochemical approach to non-small cell carcinoma of the lung in small biopsies in the context of the 2015 WHO Classification of Lung Cancer. Indian J Med Res [serial online] 2017 [cited 2019 Dec 8];146:8-10. Available from: http://www.ijmr.org.in/text.asp?2017/146/1/8/219003



About a decade ago, subtyping of non-small cell lung cancer (NSCLC) was not much of clinical relevance, as no differential treatment options were available then for specific histologic types[1],[2]. But considerable developments in the understanding of genetics of pulmonary cancers have altered the present scenario. With the discovery of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase-1 (ALK-1) mutations, which are effective targets for their corresponding inhibitors, the treatment options have opened up for certain major subsets of adenocarcinoma (ADC). Not only the targeted therapy but also the emergence of newer cytotoxic drugs with differential activity such as pemetrexed or drugs with limited indications such as bevacizumab have made the precise histologic typing obligatory[1],[3],[4],[5],[6],[7].

Keeping in mind the changed scenario, essential modifications are made in the recent classifications of lung cancer including the recently adopted 2015 WHO Classification, which radically differs from its 2014 counterpart[1]. The major changes are chiefly with regard to common pulmonary malignancies such as ADC and squamous cell carcinoma (SQC) that morphologically manifest as non-small cell carcinomas (NSCCs). The changes in the current WHO Classification are greatly influenced by the 2011 Classification of Lung ADCs sponsored by the International Association for the Study of Lung Cancer (IASLC), the American Thoracic Society (ATS) and the European Respiratory Society (ERS)[1]. The highlight of the IASLC/ATS/ERS Classification is that it incorporates the diagnosis of pulmonary cancers on cytologic and small biopsy specimens[1].

As per the literature, about two-thirds of patients with lung carcinomas present in advanced stages, where the diagnosis is established usually through small biopsies or cytologic specimens. Thus, the points that are highlighted here from the currently relevant classification systems are pertaining either directly or indirectly to small biopsy/cytologic diagnosis of NSCCs. One essential aspect of the current WHO Classification is that it provides the standardized diagnostic criteria and terminologies for lung cancer on small biopsy and cytologic specimens. With the introduction of screening programmes for lung cancer, the small biopsy/cytologic materials are not only likely to assist in diagnosing malignancy at an early stage but also have the potential for providing the molecular diagnosis for targeted therapy; if pathologists can effectively manage to preserve sufficient material for molecular testing[1].

The current WHO Classification delves more into practical issues and strongly emphasizes the importance of immunohistochemistry (IHC) not only on small biopsy/cytologic material but also on resected specimens. The 2004 WHO Classification had restricted the use of IHC to tumours such as large cell neuroendocrine carcinoma (LCNEC), sarcomatoid carcinoma and carcinomas that needed to be differentiated from mesothelioma. With respect to IHC, the 2015 WHO Classification stresses the need for a high-quality immunostaining and also participation of laboratories in external quality assurance programme to ensure accurate diagnoses[1].

According to the literature, the proportion of NSCCs categorized as not otherwise specified (NSCC-NOS) on small biopsies ranges between 30 and 50 per cent; however, currently, there has been a drastic shift in it with the established therapeutic implications of the precise histologic diagnosis[1],[8]. According to the current WHO Classification, biopsies or cytologic smears from NSCCs exhibiting acinar, papillary, lepidic and micropapillary patterns can be categorized as ADC while those with keratinization and intercellular bridges can be reported as SQC even without IHC/immunocytochemistry (ICC) support. It recommends a limited ICC/IHC workup with the preservation of material for molecular testing in cases of poorly differentiated NSCCs lacking obvious squamous or glandular differentiation. NSCCs lacking both morphologic and IHC evidence of squamous or glandular differentiation should be reported as NSCC-NOS rather than non-small cell lung cancer (NSCLC). The alphabet L is excluded to keep open the possibility of metastasis. The tumours with cells expressing ‘only thyroid transcription factor-1 (TTF-1)’ and ‘only p63 or p40’ should be reported as ‘NSCC favour ADC’ and ‘NSCC favour SQC’, respectively, while a tumour with two different populations of cells separately expressing ADC and SQC markers should raise a suspicion of adenosquamous carcinoma, though its definitive diagnosis is possible only on resected specimens. SQCs are reclassified in the 2015 WHO Classification into keratinizing, non-keratinizing and basaloid subtypes, of which the non-keratinizing type always needs an IHC confirmation[1].

There have been considerable numbers of studies dealing with IHC in NSCCs on small biopsies/cell block specimens to differentiate between ADC and SQC[5],[9],[10],[11]. Common markers used for ADCs are TTF-1[5], napsin A[10] and CK7[12]; while SQC markers evaluated are CK5/6, p63[7],[9],[10], 34ßE[5], p40[6],[10],[13], desmoglein, desmocollin[8], high molecular weight cytokeratins and S-100A7[2]. Of the important ADC markers, sensitivity and specificity of TTF-1 have been shown to range between 80.0-84.5 and 89.0-96.4 per cent, respectively; while Napsin A has been shown to be 58-92 per cent sensitive and 100 per cent specific[9],[12]. Of the significant SQC markers, CK5/6 has been shown to be 73-100 per cent sensitive and 77.8-100 per cent specific[9],[12]; while p63 has been shown to be 87-100 per cent sensitive and 78.3-92 per cent specific[7],[9]. However, a sensitive marker, p63 is less specific, with a considerable proportion of ADCs and other tumours such as lymphomas (54%) also expressing it[6]. Sensitivity of the relatively newer SQC marker p40 is said to be comparable to that of p63[9] and hence considered the best among the existing SQC marker[13].

Although initial studies, as well as some of the recent studies, have dealt with the utility of multiple ADC and SQC markers[2],[5],[9],[10],[11],[12], the current emphasis on the need for preservation of material for molecular testing has prompted a search for a reliable minimalistic 2-marker panel with one each of ADC and SQC markers[13]. The article by Walia et al[14] in this issue addresses this aspect with a fairly good sample size. The fact that their approach could bring down the number of NSCCs from 46.7 to mere 14.2 per cent and that 85.5 per cent of NSCCs could accurately be classified into ADC and SQC reflects the high effectiveness and practical utility of the 2-marker panel of TTF-1 and p40. The 100 per cent sensitivity and specificity documented for p40 in their study support and strengthened the claim that ‘p40 is the best currently available SQC marker’. The only significant similar study in the Western literature is that of Pelosi et al[13]. As the authors have themselves admitted, the low number of resected specimens used for validation is one of the limitations of the study, which, however, has rightly been attributed by the authors to common presentation of NSCC patients at an advanced stage, not amenable to resection. Furthermore, as the study was designed before the implementation of the 2015 WHO Classification, it is understandable that the 2011 ASCLC/ATS/ERS terminologies such as ‘non-small cell lung cancer’ and ‘NSCLC’ are retained in the study. The observations that two of their cases morphologically diagnosed as ADC and NSCLC-NOS turned out to be adenosquamous and sarcomatoid carcinomas emphasize the importance of IHC on resected specimens[14]. Sensitivity and specificity of ADC marker TTF-1 documented by the authors[14] remain similar to that in the literature[9],[12].

Mucin stains were not used in this study due to their low sensitivity, as well as with the intention of saving tissue sample for molecular studies[14]. In the recent years, with easy access to IHC markers, the role of mucin stains such as Alcian blue/periodic acid–Schiff (AB/PAS) is ignored. Although not all ADCs express mucin with routine histochemical stains, the stainable mucin still remains one of the defining characteristics of pulmonary ADC[15]. Loo et al[2] documented 23 per cent sensitivity and 100 per cent specificity for mucin with a 100 per cent positive and 76 per cent negative predictive values in pulmonary ADCs. Despite the limited published data on mucin stains in pulmonary ADCs, AB/PAS stains would retain a high probability of staining central bronchial type or poorly differentiated ADCs that are likely to be TTF-1 negative[2].

The current WHO Classification restricts the diagnosis of large cell carcinomas to resected tumours lacking obvious morphologic or IHC differentiation. Notably, it also puts the entire spectrum of pulmonary neuroendocrine tumours, including the LCNEC as a single group[1]. LCNECs account for 2.1-3.5 per cent of all lung cancers. Although LCNECs exhibit neuroendocrine architecture on histology (which may not be consistently reflected in small biopsies), cytologically, these resemble large cell carcinomas with polygonal cells having abundant cytoplasm, variably granular pattern of chromatin and atypical or clear nucleoli. Thus, with the absence of classic neuroendocrine cytologic features, these can easily be mistaken for NSCC-NOS type or even ADC on small biopsies, the management of which are entirely different. However, a high mitotic activity of ≥11/10 hpf and more abundant necrosis (prominent features of LCNEC) are often helpful in distinguishing these from ADCs that tend to have fewer mitoses and less abundant necrosis[16]. The issue of LCNECs has not been addressed by Walia et al[14] as it was out of scope of their study design. Obviously, none of their resected cases represented LCNECs. However, with no mention of neuroendocrine markers being performed in their NSCC-NOS cases, probability of any of these being LCNECs remains unresolved. Zhang et al[10] documented neuroendocrine tumours including LCNEC to be consistently negative for SQC markers such as p63, p40 and CK5/6 while Pelosi et al[13] reported ignorably low scores of p63 and p40 in LCNECs. LCNEC has also been shown to be negative for napsin-A and TTF-1[10]. Thus, with the 2-marker approach, LCNEC will be interpreted as ‘NSCC-NOS’, wherein use of at least one highly sensitive neuroendocrine marker (after the 2-marker panel) would be of considerable help.



 
   References Top

1.
Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization classification of lung tumors. J Thorac Oncol 2015; 10 : 1243-60.  Back to cited text no. 1
[PUBMED]    
2.
Loo PS, Thomas SC, Nicolson MC, Fyfe MN, Kerr KM. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol 2010; 5 : 442-7.  Back to cited text no. 2
[PUBMED]    
3.
Ho C, Tong KM, Ramsden K, Ionescu DN, Laskin J. Histologic classification of non-small-cell lung cancer over time: Reducing the rates of not-otherwise-specified. Curr Oncol 2015; 22 : e164-70.  Back to cited text no. 3
[PUBMED]    
4.
Zugazagoita J, Enguita AE, Nunez JA, Iglesias L, Ponce S. The new IASCL/ATS/ERS lung adenocarcinoma classification from a clinical perspective: Current concepts and future prospects. J Thorac Dis 2014; 6 (Suppl 5) : S526-36.  Back to cited text no. 4
    
5.
Rekhtman N, Ang DC, Sima CS, Travis WD, Moreira AL. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol 2011; 24 : 1348-59.  Back to cited text no. 5
[PUBMED]    
6.
Bishop JA, Teruya-Feldstein J, Westra WH, Pelosi G, Travis WD, Rekhtman N. p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol 2012; 25 : 405-15.  Back to cited text no. 6
[PUBMED]    
7.
Ma Y, Fan M, Dai L, Kang X, Liu Y, Sun Y, et al. Expression of p63 and CK5/6 in early-stage lung squamous cell carcinoma is not only an early diagnostic indicator but also correlates with a good prognosis. Thorac Cancer 2015; 6 : 288-95.  Back to cited text no. 7
[PUBMED]    
8.
Righi L, Vavalà T, Rapa I, Vatrano S, Giorcelli J, Rossi G, et al. Impact of non-small-cell lung cancer-not otherwise specified immunophenotyping on treatment outcome. J Thorac Oncol 2014; 9 : 1540-6.  Back to cited text no. 8
    
9.
Mukhopadhyay S, Katzenstein ALA. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol 2011; 35 : 15-25.  Back to cited text no. 9
    
10.
Zhang C, Schmidt LA, Hatanaka K, Thomas D, Lagstein A, Myers JL. Evaluation of napsin A, TTF-1, p63, p40, and CK5/6 immunohistochemical stains in pulmonary neuroendocrine tumors. Am J Clin Pathol 2014; 142 : 320-4.  Back to cited text no. 10
[PUBMED]    
11.
Zhao W, Wang H, Peng Y, Tian B, Peng L, Zhang DC. ΔNp63, CK5/6, TTF-1 and napsin A, a reliable panel to subtype non-small cell lung cancer in biopsy specimens. Int J Clin Exp Pathol 2014; 7 : 4247-53.  Back to cited text no. 11
[PUBMED]    
12.
Gurda GT, Zhang L, Wang Y, Chen L, Geddes S, Cho WC, et al. Utility of five commonly used immunohistochemical markers TTF-1, Napsin A, CK7, CK5/6 and P63 in primary and metastatic adenocarcinoma and squamous cell carcinoma of the lung: A retrospective study of 246 fine needle aspiration cases. Clin Transl Med 2015; 4 : 16.  Back to cited text no. 12
[PUBMED]    
13.
Pelosi G, Fabbri A, Bianchi F, Maisonneuve P, Rossi EG, Barbareschi M, et al. ΔNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: A novel two-hit, sparing-material approach. J Thorac Oncol 2012; 7 : 281-90.  Back to cited text no. 13
    
14.
Walia R, Jain D, Madan K, Sharma MC, Mathur SR, Mohan A, et al. p40 & thyroid transcription factor-1 immunohistochemistry: A useful panel to characterize non-small cell lung carcinoma, not otherwise specified (NSCLC-NOS) category. Indian J Med Res 2017; 146 : 42-8.  Back to cited text no. 14
    
15.
Schreiber G, McCrory DC. Performance characteristics of different modalities for diagnosis of suspected lung cancer: Summary of published evidence. Chest 2003; 123 (1 Suppl) : 115S-28S.  Back to cited text no. 15
    
16.
Fasano M, Della Corte CM, Papaccio F, Ciardiello F, Morgillo F. Pulmonary large-cell neuroendocrine carcinoma: From epidemiology to therapy. J Thorac Oncol 2015; 10 : 1133-41.  Back to cited text no. 16
[PUBMED]    




 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    References

 Article Access Statistics
    Viewed547    
    Printed3    
    Emailed0    
    PDF Downloaded193    
    Comments [Add]    

Recommend this journal